US EditionFirst-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma
Summary by onclive.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Astrazeneca’s Calquence Combination Recommended for EU Approval in Untreated MCL Patients
AstraZeneca’s Calquence (acalabrutinib), in combination with bendamustine and rituximab, has been recommended for approval in the European Union (EU). This treatment targets adult patients with … Astrazeneca’s Calquence Combination Recommended for EU Approval in Untreated MCL Patients Read More » The post Astrazeneca’s Calquence Combination Recommended for EU Approval in Untreated MCL Patients first appeared on GeneOnline News. The post Astrazen…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
